Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo. “Digital Trust” provides services within the digital security sector, offering IT solutions for...
2025-06-25 1:06 AM EDT
Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center
Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that in July 2025, it will initiate their first usability study of a medical device software application connecting the Medtronic GI Genius™ intelligent endoscopy module, an AI-powered platform for gastrointestinal endoscopy, with Apple Vision Pro. The study, to be conducted at Rush University Medical Center in Chicago under the leadership of Irving Waxman, MD, James R. Lowenstine...
2025-06-24 1:06 AM EDT
Voting Results of Cosmo's 2025 AGM
Dublin, Ireland--(Newsfile Corp. - May 30, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting. A total of 9,135,061 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 52.07% of the total outstanding ordinary shares in the share capital of Cosmo as of the record date. Among others, the shareholders of...
2025-05-30 9:10 AM EDT
Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025
Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal (GI) drug development. DDW is the world’s premier gathering in the field, attracting each year over 13,000 gastroenterologists, researchers, and industry leaders from...
2025-05-05 12:59 AM EDT
Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem
Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification[1] for Cerebro, a Real-Time AI-powered guide for complete Esophagogastroduodenoscopy (EGD) procedures. As one of the first Computer-Assisted Quality (CAQ) tools for endoscopy, Cerebro marks a significant step forward in transforming procedures by elevating inspection quality, standardizing protocols, and...
2025-05-02 1:08 AM EDT
Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)
Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Following the recent CHMP opinion regarding the marketing authorization application for Winlevi® (clascoterone cream 1%) in Europe, Cosmo Pharmaceuticals N.V. (SIX: COPN) confirms that its financial guidance for 2025 remains unchanged. While the company is disappointed by the opinion, it maintains strong confidence in the clinical profile of Winlevi® and its potential to address a significant unmet need in dermatology. The outcome of the...
2025-04-29 9:11 AM EDT
Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision
Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application (MAA) for Winlevi® (clascoterone cream 1%) for the treatment of acne vulgaris. The opinion is principally based on the CHMP’s negative benefit-risk assessment on the therapeutic use of Winlevi in adolescents (12 to 17 years...
2025-04-29 1:25 AM EDT
Cosmo Publishes Agenda of AGM 2025
Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo” or the “Company”) today announced the convening of its Annual General Meeting 2025 to be held on Friday 30 May 2025, at 12:00 CEST, at Strawinskyhuis, Prinses Amaliaplein 3, 1077 XS Amsterdam, the Netherlands. The agenda includes, inter alia, the following discussion and voting items: Report of the Board of Directors on the financial year ended 31 December 2024 Approval of the...
2025-04-29 1:04 AM EDT
Cosmo Appoints Federico Sommariva as Chief Legal Counsel
Dublin, Ireland--(Newsfile Corp. - April 1, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as...
2025-04-01 1:02 AM EDT
Cosmo Pharmaceuticals publishes Annual Report 2024
Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year results on March 6, 2025, the reporting year was characterized by strong financial performance, exceptional revenue growth, significant strategic advancements, and a clear roadmap for future sustained corporate developments. The key highlights from...
2025-03-21 2:13 AM EDT
Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025
Dublin, Ireland--(Newsfile Corp. - March 6, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today reported its unaudited results for the fiscal year ending December 31, 2024. The consolidated and audited 2024 Full-Year results along with the 2024 Annual Report and ESG Report will be published on March 21, 2025.
2025-03-06 1:01 AM EST
Cosmo to Host Investor Day on April 9, 2025
Dublin, Ireland--(Newsfile Corp. - February 12, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce that it will host an Investor Day on Wednesday, April 9, 2025. The live event will be held at the Hotel “Park Hyatt” at Beethovenstrasse 21 in 8002 Zurich, Switzerland. The presentation will begin at 11:00am CET and will be followed by lunch. Cosmo’s Investor Day event will include presentations from the Management team on Cosmo’s R&D pipeline, long-term...
2025-02-12 1:01 AM EST
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
Dublin, Ireland--(Newsfile Corp. - February 11, 2025) - Planet Friendly Technologies, Inc.Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea...
2025-02-11 1:02 AM EST
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne
India and London, United Kingdom--(Newsfile Corp. - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi® in the United Kingdom. Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a...
2025-02-10 1:02 AM EST
Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025
Dublin, Ireland--(Newsfile Corp. - January 28, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET. Live conference call and video webcast presentation: Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same day at 3:00 pm CET. Giovanni Di Napoli, Chief Executive Officer, and...
2025-01-28 5:49 AM EST
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
Dublin, Ireland--(Newsfile Corp. - January 9, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) r
2025-01-09 1:07 AM EST
Cosmo Pharmaceuticals Appoints Chief Strategy Officer
Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus on strategy-led growth and innovation. She will be reporting to the CEO. Dominika brings over 15 years of diverse experience in and outside of the Life Sciences industry, as...
2024-12-12 1:02 AM EST
Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM
Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024. Cosmo’s previous auditor was appointed as independent auditor in 2016. Having given consideration to good governance practices in relation to rotation of auditors, the Board of...
2024-10-18 10:27 AM EDT
Cosmo Pharmaceuticals Appoints New Chief Financial Officer
Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion...
2024-10-11 1:06 AM EDT
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development
Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations and driving strategic market growth, Egle is a valuable addition to Cosmo’s management team, as the Company...
2024-09-23 1:10 AM EDT